Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass

Science Translational Medicine

Volumn 2, Issue 19, 2010, Pages

  Alcock, Robert ^a,d   Cottingham, Matthew G ^b   Rollier, Christine S ^b   Furze, Julie ^b   De Costa, Samodh D ^a,c   Hanlon, Marian ^a   Spencer, Alexandra J ^b   Honeycutt, Jared D ^b   Wyllie, David H ^b   Gilbert, Sarah C ^b   Bregu, Migena ^b   Hill, Adrian V S ^b  

^a Cambridge Biostability Ltd   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Martin House   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; LIVE VACCINE; STABILIZING AGENT; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DESICCATION; EMBRYO; ENVIRONMENTAL TEMPERATURE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LONG TERM EXPOSURE; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; SEROTYPE; TEMPERATURE DEPENDENCE; THERMOSTABILITY; VACCINE PRODUCTION; VIRUS LOAD; VITRIFICATION;

ADENOVIRIDAE; CARBOHYDRATES; DRUG STORAGE; GENETIC VECTORS; GLASS; HUMANS; SUCROSE; TREHALOSE; VACCINIA VIRUS; VIRAL VACCINES;

EID: 77953013744     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000490     Document Type: Article

References (36)

1. C. D. Mathers, T. Boerma, D. Ma Fat, The Global Burden of Disease: 2004 Update (World Health Organization, Geneva, 2004).
2. J. Rexroad, C. M. Wiethoff, L. S. Jones, C. R. Middaugh, Lyophilization and the thermostability of vaccines. Cell Preserv. Technol. 1, 91-104 (2002).
3. J. Cohen, Public health. Gates Foundation picks winners in Grand Challenges in Global Health. Science 309, 33-35 (2005).
4. R. Walgate, Gates Foundation picks 14 grand challenges for global disease research. Bull. World Health Organ. 81, 915-916 (2003).
5. J. Lloyd, Technologies for Vaccine Delivery in the 21st Century (World Health Organization, Geneva, 2000).
6. M. Sakurai, T. Furuki, K. Akao, D. Tanaka, Y. Nakahara, T. Kikawada, M. Watanabe, T. Okuda, Vitrification is essential for anhydrobiosis in an African chironomid, Polypedilum vanderplanki. Proc. Natl. Acad. Sci. U.S.A. 105, 5093-5098 (2008).
7. J. H. Crowe, Trehalose as a "chemical chaperone": Fact and fantasy. Adv. Exp. Med. Biol. 594, 143-158 (2007).
8. A. B. Richards, S. Krakowka, L. B. Dexter, H. Schmid, A. P. Wolterbeek, D. H. Waalkens-Berendsen, A. Shigoyuki, M. Kurimoto, Trehalose: A review of properties, history of use and human tolerance, and results of multiple safety studies. Food Chem. Toxicol. 40, 871-898 (2002).
9. G. Iturriaga, R. Suárez, B. Nova-Franco, Trehalose metabolism: From osmoprotection to signaling. Int. J. Mol. Sci. 10, 3793-3810 (2009).
10. C. E. Gómez, J. L. Nájera, M. Krupa, M. Esteban, The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8, 97-120 (2008).
11. M. J. Imperiale, S. Kochanek, Adenovirus vectors: Biology, design, and production. Curr. Top. Microbiol. Immunol. 273, 335-357 (2004).
12. N. Tatsis, H. C. Ertl, Adenoviruses as vaccine vectors. Mol. Ther. 10, 616-629 (2004).
13. S. C. Gilbert, V. S. Moorthy, L. Andrews, A. A. Pathan, S. J. McConkey, J. M. Vuola, S. M. Keating, T. Berthoud, D. Webster, H. McShane, A. V. Hill, Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24, 4554-4561 (2006).
14. S. P. Buchbinder, D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, M. N. Robertson; Step Study Protocol Team, Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
15. T. Hanke, STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev. Vaccines 7, 303-309 (2008).
16. K.McCoy, N. Tatsis, B. Korioth-Schmitz, M.O. Lasaro, S. E.Hensley, S. W. Lin, Y. Li, W.Giles-Davis, A. Cun, D. Zhou, Z. Xiang, N. L. Letvin, H. C. Ertl, Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81, 6594-6604 (2007).
17. M. J. McElrath, S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, S. P. Buchbinder, M. N. Robertson, D. V. Mehrotra, S. G. Self, L. Corey, J. W. Shiver, D. R. Casimiro; Step Study Protocol Team, HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 372, 1894-1905 (2008).
18. A. V. Hill, Pre-erythrocytic malaria vaccines: Towards greater efficacy. Nat. Rev. Immunol. 6, 21-32 (2006).
19. T. Hanke, N. Goonetilleke, A. J. McMichael, L. Dorrell, Clinical experience with plasmid DNA and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 88, 1-12 (2007).
20. D. H. Barouch, Challenges in the development of an HIV-1 vaccine. Nature 455, 613-619 (2008).
21. H. Fletcher, H. McShane, Tuberculosis vaccines: Current status and future prospects. Expert Opin. Emerg. Drugs 11, 207-215 (2006).
22. C. Sander, H. McShane, Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis. Clin. Exp. Immunol. 147, 401-411 (2007).
23. D. F. Hoft, Tuberculosis vaccine development: Goals, immunological design, and evaluation. Lancet 372, 164-175 (2008).
24. G. F. Rimmelzwaan, G. Sutter, Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev. Vaccines 8, 447-454 (2009).
25. M. G. Cottingham, R. F. Andersen, A. J. Spencer, S. Saurya, J. Furze, A. V. Hill, S. C. Gilbert, Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 3, e1638 (2008).
26. P. Romero, J. L. Maryanski, A. S. Cordey, G. Corradin, R. S. Nussenzweig, F. Zavala, Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. Immunol. Lett. 25, 27-31 (1990).
27. S. J. Draper, A. C. Moore, A. L. Goodman, C. A. Long, A. A. Holder, S. C. Gilbert, F. Hill, A. V. Hill, Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 14, 819-821 (2008).
28. E. Segura, J. A. Villadangos, Antigen presentation by dendritic cells in vivo. Curr. Opin. Immunol. 21, 105-110 (2009).
29. J. P. Amorij, J. Meulenaar, W. L. Hinrichs, T. Stegmann, A. Huckriede, F. Coenen, H. W. Frijlink, Rational design of an influenza subunit vaccine powder with sugar glass technology: Preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25, 6447-6457 (2007).
30. M. A. Croyle, X. Cheng, J. M. Wilson, Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 8, 1281-1290 (2001).
31. K. N. Lee, C. L. Hutson, R. Kline, A. T. Curns, C. Dougherty, C. Allen, I. Damon, R. Regnery, Smallpox vaccine stability after maintenance at temperatures not recommended for shipping. Vaccine 24, 884-886 (2006).
32. B. Roser, Stable liquid vaccines and drugs for the 21st century. Future Microbiol. 1, 21-31 (2006).
33. D. M. Matthias, J. Robertson, M. M. Garrison, S. Newland, C. Nelson, Freezing temperatures in the vaccine cold chain: A systematic literature review. Vaccine 25, 3980-3986 (2007). (Pubitemid 46616996)
34. S. D. De Costa, B. Roser, S. Sen, Pharmaceutical device for the administration of substances to patients, European patent specification EP1976483 (2006).
35. S. Sridhar, A. Reyes-Sandoval, S. J. Draper, A. C. Moore, S. C. Gilbert, G. P. Gao, J. M. Wilson, A. V. Hill, Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J. Virol. 82, 3822-3833 (2008).
36. J. Schneider, S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, A. V. Hill, Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397-402 (1998).